Nodular thyroid disease surgery

Nodular thyroid disease Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Nodular thyroid disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

MRI

Ultrasound

Fine Needle Aspiration

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nodular thyroid disease surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Nodular thyroid disease surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nodular thyroid disease surgery

CDC on Nodular thyroid disease surgery

Nodular thyroid disease surgery in the news

Blogs on Nodular thyroid disease surgery

Directions to Hospitals Treating Nodular thyroid disease

Risk calculators and risk factors for Nodular thyroid disease surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Overview[edit | edit source]

## Surgery and Device Based Therapy[edit | edit source]

* The extent of surgery is also controversial. Some surgeons advocate lobectomy and isthmectomy for papillary cancers < 2cm confined to one lobe, whereas others prefer complete thyroidectomy. Larger, multicentric or locally metastatic tumors are best managed with total thyroidectomy, regional lymph node and radical neck dissection.

* For nontoxic multinodular goiter, bilateral subtotal thyroidectomy is the standard of care.
* Lifelong thyroxine replacement has been shown to reduce tumor recurrence rate. The optimal range of suppression is not clear however. If the tumor is completely removed, most authors recommend keeping the TSH ~ 0.1 ug/ml, and even lower in metastatic disease.

* The use of thyroid hormone replacement to shrink or suppress the growth of a benign nodule is controversial. Reported effectiveness is between 0 – 68%, and it seems to work better in multinodular disease.

* A recent study from the Annals suggests that only 10-20% of nodules shrink in response to therapy. Additionally, they report that post-op replacement therapy does not prevent recurrence, except in patients with a history of radiation therapy. As thyroid replacement is associated with an increased risk of osteoporosis and heart disease, they do not recommend suppressive therapy.
* For cystic lesions, FNA can be curative, whereas thyroxine replacement will usually not change the cyst at all.

### Indications for Surgery[edit | edit source]

* The indications for surgery vary widely between institutions, with rates primarily determined by the accuracy of FNA, the threshold of individual surgeons, and differing views on whether all indeterminate FNA should be removed.

## References[edit | edit source]

Template:WikiDoc Sources